1 January 2023 in Hepatology Forum
Background and Aim: Combined hepatocellular-cholangiocarcinoma (CHC) requires attention clinically and pathologically after liver transplantation (LT) because of its unique biology, difficulties in diagnosis, and being rare. We aimed to present our single center experience for this incidental combined tumor. It is aimed to present our single-center experience for this incidental combined tumor. Materials and Methods: Seventeen patients with CHC were included in the study. There were 260 hepatocellular carcinoma (HCC) patients determined as the control group. Patients were evaluated for demographic, etiological, pathological features, and survival. Results: Macrovascular and microvascular invasion levels were signifi-cantly higher in the CHC group (p
28 April 2025 in Annals of Transplantation
BACKGROUND Living donor liver transplantation (LDLT) has been shown to be safe in the curative treatment of liver cirrhosis. Portal flow modulation techniques, such as splenic artery ligation (SAL), have been used to avoid complications like small-for-size syndrome (SFSS). However, the effects of SAL on portal flow, splenic function, and hematologic outcomes remain underexplored. MATERIAL AND METHODS This retrospective study analyzed 60 LDLT recipients treated at a single center from January 2023 to December 2024. Thirty patients underwent SAL (SAL+) while 30 did not undergo SAL (SAL-). Data on demographic and clinical characteristics, portal flow dynamics, spleen volume, hematologic parameters, and postoperative complications were collected and analyzed using IBM SPSS 20.0. Statistical significance was set at P<0.05. RESULTS SAL significantly reduced portal flow from 3148±989 mL/min to 1949±830 mL/min (P<0.001), optimizing the portal flow/graft weight ratio. SAL also decreased splenic volume by 21% and alleviated thrombocytopenia, with postoperative platelet counts increasing 3.8-fold compared to preoperative levels (P<0.001). There were fewer complications in the SAL+ group, with significant reductions in biliary complications and improved graft function. No severe ischemic splenic changes or thromboembolic events were observed in the SAL+ group. CONCLUSIONS SAL is an effective strategy for portal flow modulation in LDLT, significantly reducing portal flow to optimal levels and improving hematologic outcomes. By preserving splenic function and minimizing complications, SAL is a safe and beneficial approach to managing SFSS and improving graft performance in LDLT patients.
24 February 2025 in Pediatric Transplantation
28 April 2025 in Transplantation Proceedings
14 May 2025 in Annals of Transplantation
BACKGROUND Living donor liver transplantation (LDLT) faces increasing challenges due to the rising prevalence of hepatic steatosis among potential donors. Moderate steatosis (30-60%) is particularly problematic, often leading to donor exclusion and reducing the available donor pool. Preoperative interventions aiming to reduce hepatic fat content have emerged as a potential strategy, but data regarding their safety and efficacy remain limited. MATERIAL AND METHODS This retrospective, single-center study evaluated 34 living liver donors between June 2023 and August 2024. Fourteen donors received preoperative treatment for moderate hepatic steatosis, while 20 donors with mild or no steatosis served as controls. Pre- and post-treatment assessments included body mass index (BMI), liver fat assessment via computed tomography (CT), liver function tests, and perioperative outcomes. RESULTS Preoperative treatment significantly reduced hepatic fat content, with all treated donors achieving steatosis levels below 30% (P0.05). No donor experienced serious complications during the early postoperative period or the first year of follow-up. All donors maintained satisfactory graft and remnant liver function, and no treatment-related adverse events were observed. CONCLUSIONS Preoperative management of moderate hepatic steatosis in living liver donors is effective in reducing liver fat to acceptable levels without compromising donor safety. This approach offers a promising strategy to expand the LDLT donor pool. Further large-scale, multicenter studies with extended follow-up are necessary to validate these findings.
29 June 2026 in Hitit Medical Journal
Objective:Primary sclerosing cholangitis is a chronic, progressive cholestatic liver disease that frequently leads to liver transplantation. Although liver transplantation remains the only definitive treatment for advanced disease, post-transplant recurrence may adversely influence long-term outcomes. This study aimed to evaluate recurrence rates and clinical outcomes after liver transplantation in patients with primary sclerosing cholangitis.Matherial and Methods:This retrospective single-center study included thirty-seven patients who underwent liver transplantation between December 2004 and April 2025 due to primary sclerosing cholangitis. Demographic characteristics, clinical findings, surgical approaches, medical treatments, complications, recurrence patterns, and survival outcomes were evaluated using descriptive statistical methods.Results:The cohort consisted of sixteen males and twenty-one females with a mean age of 41.9 years at the time of transplantation. The mean disease duration was 6.1 years and the mean Model for End-Stage Liver Disease score was 18.4. Inflammatory bowel disease was present in 43 percent of patients, all diagnosed with ulcerative colitis. Living donor liver transplantation was performed in thirty-six patients, while one patient received a deceased donor graft. Incidental cholangiocarcinoma was identified in two explanted livers. During follow-up, disease recurrence developed in nine patients at a mean of 45.6 months, and two patients required re-transplantation. Five-year mortality was 13.5 percent, with three deaths associated with recurrence and related complications.Conclusion:Liver transplantation provides favorable long-term survival in patients with primary sclerosing cholangitis; however, recurrence remains a significant challenge. Structured long-term surveillance, optimized medical management, and multidisciplinary follow-up are essential to improve post-transplant outcomes.